SA522441561B1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents
مُعدلات ليباز أُحادِيُّ الجلِيسِريدInfo
- Publication number
- SA522441561B1 SA522441561B1 SA522441561A SA522441561A SA522441561B1 SA 522441561 B1 SA522441561 B1 SA 522441561B1 SA 522441561 A SA522441561 A SA 522441561A SA 522441561 A SA522441561 A SA 522441561A SA 522441561 B1 SA522441561 B1 SA 522441561B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- disorders
- formula
- methods
- monoglyceride lipase
- lipase levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738600P | 2018-09-28 | 2018-09-28 | |
| PCT/IB2019/058240 WO2020065613A1 (en) | 2018-09-28 | 2019-09-27 | Monoacylglycerol lipase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA522441561B1 true SA522441561B1 (ar) | 2024-08-11 |
Family
ID=68109428
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522441561A SA522441561B1 (ar) | 2018-09-28 | 2021-03-25 | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
| SA521421575A SA521421575B1 (ar) | 2018-09-28 | 2021-03-25 | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA521421575A SA521421575B1 (ar) | 2018-09-28 | 2021-03-25 | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20200102303A1 (https=) |
| EP (1) | EP3856178B1 (https=) |
| JP (2) | JP7482116B2 (https=) |
| KR (1) | KR102911066B1 (https=) |
| CN (1) | CN113164459B (https=) |
| AU (2) | AU2019350624B2 (https=) |
| BR (1) | BR112021005896A2 (https=) |
| CA (1) | CA3111380A1 (https=) |
| CL (1) | CL2021000757A1 (https=) |
| CO (1) | CO2021003944A2 (https=) |
| CR (1) | CR20210153A (https=) |
| DO (1) | DOP2021000051A (https=) |
| EA (1) | EA202190886A1 (https=) |
| EC (1) | ECSP21021381A (https=) |
| IL (1) | IL281812A (https=) |
| JO (1) | JOP20210058A1 (https=) |
| MA (1) | MA53721A (https=) |
| MX (1) | MX2021003737A (https=) |
| MY (1) | MY205440A (https=) |
| NI (1) | NI202100023A (https=) |
| PE (1) | PE20211773A1 (https=) |
| PH (1) | PH12021550659A1 (https=) |
| SA (2) | SA522441561B1 (https=) |
| SG (1) | SG11202102281VA (https=) |
| TW (1) | TWI863931B (https=) |
| WO (1) | WO2020065613A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| EP3856178B1 (en) | 2018-09-28 | 2026-03-11 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| US20220315602A1 (en) * | 2019-06-04 | 2022-10-06 | Hager Biosciences, Llc | Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists |
| MX2022003819A (es) * | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
| BR112022019077A2 (pt) * | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| WO2022150962A1 (en) * | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
| US20240270743A1 (en) * | 2021-08-11 | 2024-08-15 | Landos Biopharma, Inc. | Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof |
| AR127955A1 (es) | 2021-12-16 | 2024-03-13 | Hoffmann La Roche | Nuevos compuestos heterocíclicos |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| CN115872995B (zh) * | 2022-12-27 | 2024-10-01 | 上海凌凯科技股份有限公司 | 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法 |
| CN116606298A (zh) * | 2023-05-26 | 2023-08-18 | 康化（上海）新药研发有限公司 | 2,3-二氢-[1,4]二噁烷并[2,3-b]吡啶-8-羧酸的合成方法 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| WO1992005784A1 (en) | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
| JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
| CA2493625A1 (en) | 2002-07-25 | 2004-02-19 | Pharmacia Italia S.P.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| FR2857363B1 (fr) | 2003-07-10 | 2007-09-07 | Aventis Pharma Sa | 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation |
| AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
| ATE546452T1 (de) | 2003-09-23 | 2012-03-15 | Vertex Pharma | Pyrazolopyrrolderivate als proteinkinaseinhibitoren |
| AU2005277283A1 (en) | 2004-08-23 | 2006-03-02 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
| US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| WO2006110516A1 (en) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Acylhydrazide p2x7 antagonists and uses thereof |
| JP2009531390A (ja) | 2006-03-31 | 2009-09-03 | ノバルティス アクチエンゲゼルシャフト | 有機化合物 |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| FR2915197B1 (fr) | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| US8349858B2 (en) | 2007-06-21 | 2013-01-08 | Merck Sharp & Dohme | Polycyclic guanine derivatives and use thereof |
| WO2009023623A1 (en) | 2007-08-10 | 2009-02-19 | H, Lundbeck A/S | Heteroaryl amide analogues |
| FR2921342B1 (fr) | 2007-09-20 | 2010-03-12 | Airbus France | Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| CA2722035C (en) | 2008-04-22 | 2016-10-11 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted p2x7 antagonists |
| EP2370437B1 (en) | 2008-11-25 | 2013-09-04 | Nerviano Medical Sciences S.r.l. | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents |
| WO2010066629A2 (en) | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| WO2010124122A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| US8455476B2 (en) | 2009-04-22 | 2013-06-04 | Janssen Pharmaceutica, Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| ES2590987T3 (es) | 2009-04-29 | 2016-11-24 | Glaxo Group Limited | Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7 |
| GB0907515D0 (en) | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
| US8871760B2 (en) | 2009-09-21 | 2014-10-28 | Roche Palo Alto Llc | [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| EP2552920B1 (en) | 2010-04-02 | 2017-03-15 | Ogeda Sa | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| EP2558661A4 (en) | 2010-04-16 | 2014-10-29 | Fernandez Rodrigo Graf | FOLDABLE STRUCTURES FOR CONSTRUCTION |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| US20130196986A1 (en) | 2010-09-21 | 2013-08-01 | Marc Labroli | Triazolopyrazinones as p2x7 receptor antagonists |
| JP2013537920A (ja) * | 2010-09-27 | 2013-10-07 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ阻害剤としてのオキソピペラジン−アゼチジンアミド及びオキソジアゼピン−アゼチジンアミド |
| WO2012054716A1 (en) | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv. | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| JP2013540160A (ja) * | 2010-10-22 | 2013-10-31 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ阻害剤としてのアミノ−ピロリジン−アゼチジンジアミド |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| WO2013050424A1 (en) | 2011-10-03 | 2013-04-11 | Euroscreen S.A. | NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF |
| EP2766345B1 (en) * | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| US9273947B2 (en) | 2012-02-07 | 2016-03-01 | Lg Innotek Co., Ltd. | Sensing magnet apparatus for motor |
| JP5205547B1 (ja) | 2012-04-20 | 2013-06-05 | 株式会社ノイズ研究所 | 放射信号可視化装置 |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| MX2015004721A (es) | 2012-10-15 | 2016-01-25 | Epizyme Inc | Compuestos de benceno sustituidos. |
| MY189505A (en) | 2012-10-16 | 2022-02-16 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of roryt |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| US9796729B2 (en) | 2012-11-23 | 2017-10-24 | Glaxosmithkline Llc | Compounds as diacylglycerol acyltransferase inhibitors |
| WO2014100818A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2014214846A1 (en) | 2013-02-08 | 2015-07-23 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| PT2964229T (pt) | 2013-03-06 | 2020-03-23 | Janssen Pharmaceutica Nv | Moduladores de piridina benzimidazol-2-ilo do recetor h4 de histamina |
| NO335177B1 (no) | 2013-03-06 | 2014-10-13 | Cambi Technology As | Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse |
| SG11201507255QA (en) | 2013-03-14 | 2015-10-29 | Newlink Genetics Corp | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| NZ710765A (en) | 2013-03-14 | 2020-05-29 | Glaxosmithkline Ip No 2 Ltd | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
| CN105209449B (zh) | 2013-03-14 | 2019-02-01 | 库拉德夫制药私人有限公司 | 犬尿氨酸途径的抑制剂 |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| ES2654288T3 (es) | 2013-03-14 | 2018-02-13 | Janssen Pharmaceutica, N.V. | Moduladores de P2X7 |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| JP6275242B2 (ja) | 2013-03-29 | 2018-02-07 | オゲダ エス．エー． | 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８−メチル）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法 |
| US20150057260A1 (en) | 2013-08-22 | 2015-02-26 | Genentech, Inc. | Alkynyl alcohols and methods of use |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| AU2015314851B2 (en) | 2014-09-11 | 2020-01-02 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| CA2960968A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| WO2016039983A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
| RU2742305C2 (ru) | 2014-12-30 | 2021-02-04 | Новира Терапьютикс, Инк. | Производные и способы лечения инфекций гепатита в |
| US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TN2017000544A1 (en) | 2015-07-31 | 2019-04-12 | Pfizer | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| US10934276B2 (en) | 2016-12-16 | 2021-03-02 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| CN110198944A (zh) | 2017-01-23 | 2019-09-03 | 辉瑞大药厂 | 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物 |
| WO2020065614A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| EP3856178B1 (en) | 2018-09-28 | 2026-03-11 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| WO2020211798A1 (zh) | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| MX2022003819A (es) | 2019-09-30 | 2022-05-11 | Janssen Pharmaceutica Nv | Ligandos de pet de mgl radiomarcados. |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
-
2019
- 2019-09-27 EP EP19780427.1A patent/EP3856178B1/en active Active
- 2019-09-27 WO PCT/IB2019/058240 patent/WO2020065613A1/en not_active Ceased
- 2019-09-27 TW TW108135035A patent/TWI863931B/zh active
- 2019-09-27 JO JOP/2021/0058A patent/JOP20210058A1/ar unknown
- 2019-09-27 KR KR1020217012874A patent/KR102911066B1/ko active Active
- 2019-09-27 MX MX2021003737A patent/MX2021003737A/es unknown
- 2019-09-27 MA MA053721A patent/MA53721A/fr unknown
- 2019-09-27 EA EA202190886A patent/EA202190886A1/ru unknown
- 2019-09-27 PE PE2021000405A patent/PE20211773A1/es unknown
- 2019-09-27 AU AU2019350624A patent/AU2019350624B2/en not_active Expired - Fee Related
- 2019-09-27 MY MYPI2021001575A patent/MY205440A/en unknown
- 2019-09-27 US US16/586,088 patent/US20200102303A1/en not_active Abandoned
- 2019-09-27 JP JP2021517202A patent/JP7482116B2/ja active Active
- 2019-09-27 BR BR112021005896-6A patent/BR112021005896A2/pt unknown
- 2019-09-27 CN CN201980078969.1A patent/CN113164459B/zh active Active
- 2019-09-27 CA CA3111380A patent/CA3111380A1/en active Pending
- 2019-09-27 SG SG11202102281VA patent/SG11202102281VA/en unknown
- 2019-09-27 CR CR20210153A patent/CR20210153A/es unknown
-
2020
- 2020-12-23 US US17/132,313 patent/US11820766B2/en active Active
-
2021
- 2021-03-22 PH PH12021550659A patent/PH12021550659A1/en unknown
- 2021-03-25 CL CL2021000757A patent/CL2021000757A1/es unknown
- 2021-03-25 DO DO2021000051A patent/DOP2021000051A/es unknown
- 2021-03-25 SA SA522441561A patent/SA522441561B1/ar unknown
- 2021-03-25 SA SA521421575A patent/SA521421575B1/ar unknown
- 2021-03-25 IL IL281812A patent/IL281812A/en unknown
- 2021-03-26 NI NI202100023A patent/NI202100023A/es unknown
- 2021-03-26 EC ECSENADI202121381A patent/ECSP21021381A/es unknown
- 2021-03-29 CO CONC2021/0003944A patent/CO2021003944A2/es unknown
-
2022
- 2022-12-06 US US18/062,484 patent/US12577243B2/en active Active
-
2024
- 2024-03-19 JP JP2024043368A patent/JP2024096702A/ja active Pending
-
2025
- 2025-09-03 AU AU2025226693A patent/AU2025226693A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA522441561B1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
| JOP20220180A1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
| JOP20210154B1 (ar) | مثبطات kif18a | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| EA201100461A1 (ru) | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования | |
| EA201591614A1 (ru) | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
| MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
| MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
| MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
| MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
| CY1124346T1 (el) | ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX388696B (es) | Derivados de oxazina como inhibidores de beta secretasa y metodos de uso. | |
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. | |
| WO2020219486A9 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| MX2024010344A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| EA202092290A1 (ru) | Ингибиторы bcl6 | |
| WO2021099966A3 (en) | Novel benzothiophene derivatives and use thereof for stimulating mitochondrial turnover | |
| EP4408347A4 (en) | IMPLANTABLE MATRIX FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | |
| MX2024005997A (es) | Antagonistas del receptor de adenosina. | |
| EA202191938A1 (ru) | Производные 2h-индазола в качестве терапевтических средств при видах рака головного мозга и метастазах в головной мозг |